GRI Bio, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- W. Marc Hertz
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2223 Avenida de la Playa La Jolla CA United States of America 92037
- IPO Date
- Feb 10, 2021
- CIK
- 0001824293
- Website
- gribio.com
- Similar Companies
- Business
- GRI Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for inflammatory, fibrotic, and autoimmune conditions across the United States. Its robust pipeline features several promising candidates, including GRI-0621, which is currently in Phase 2a clinical development, targeting severe fibrotic lung diseases such as idiopathic pulmonary fibrosis. Another key asset, GRI-0803, is in preclinical stages, with plans for Phase 1 trials focusing on autoimmune disorders like systemic lupus erythematosus. The company also maintains a substantial library of over 500 proprietary compounds aimed at modulating Natural Killer T (NKT) cells, which are crucial regulators early in the inflammatory cascade, to restore immune system balance. Earlier in 2023, the entity, formerly known as Glycoregimmune, Inc., completed a merger that significantly advanced its NKT cell modulator pipeline. GRI Bio, Inc. was established in 2009 and operates from its headquarters in La Jolla, California.
Banner Bank Releases New Corporate Responsibility Report
Asbury Automotive Group Named in TIME America's Best Companies 2026 List
Luxshare Precision Releases 2025 Sustainability Report
CROWN HOLDINGS ANNOUNCES PUBLICATION OF ITS 2025 SUSTAINABILITY REPORT "DELIVERING SUSTAINABILITY", HIGHLIGHTING KEY MILESTONES AND PROGRESS TOWARD 2030 GOALS
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
The Toro Company Publishes 2025 Global Sustainability Impact Report
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
Immuneering (NASDAQ:IMRX) vs. GRI Bio (NASDAQ:GRI) Head-To-Head Survey
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
GRI Bio Announces Reverse Stock Split
GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621
GRI Bio Announces Closing of $8.0 Million Public Offering
GRI Bio Announces Pricing of $8,000,000 Million Public Offering